Vandetanib and indwelling pleural catheter for non-small cell lung cancer with recurrent malignant pleural effusion

BACKGROUND: Non-small-cell lung cancer patients with malignant pleural effusion have a poor overall median survival (4.3 months). Vascular endothelial growth factor (VEGF) is a key regulator of pleural effusion production. It is unknown if pharmacological inhibition of VEGF signaling modifies the di...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Massarelli, Erminia, Onn, Amir, Marom, Edith M., Alden, Christine M., Liu, Diane D., Tran, Hai T., Mino, Barbara, Wistuba, Ignacio I., Faiz, Saadia A., Bashoura, Lara, Eapen, George A., Morice, Rodolfo C., Jack Lee, J., Hong, Waun K., Herbst, Roy S., Jimenez, Carlos A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160385/
https://ncbi.nlm.nih.gov/pubmed/24913066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2014.04.002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi